Recent Comments

Comment RSS

Gabapentin News and Research RSS Feed - Gabapentin News and Research

Gabapentin (brand name Neurontin) is a medication originally developed for the treatment of epilepsy. Presently, gabapentin is widely used to relieve pain, especially neuropathic pain.

Astellas Pharma and XenoPort submit NDA in Japan for PMDA approval

19. November 2009 07:06
Astellas Pharma Inc. and XenoPort, Inc. today announced that a new drug application (NDA) has been filed with the Pharmaceuticals and Medical Device Agency (PMDA) in Japan for ASP8825 (gabapentin enacarbil), also known as XP13512, as a potential treatment for restless legs syndrome (RLS). [More]

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , , , , , ,

Permalink | Comments (0)

EpiCept announces third quarter 2009 financial results

10. November 2009 00:45
EpiCept Corporation today announced operating and financial results for the three and nine months ended September 30, 2009, and provided an update on Ceplene® and several of the Company’s key product candidates. [More]

Posted in: Business / Finance

Tags: , , , , , , , , , , , , , , , , ,

Permalink | Comments (0)

FDA extends review date of New Drug Application for GSK1838262/XP13512

7. November 2009 01:31
GlaxoSmithKline and XenoPort, Inc. (Nasdaq: XNPT) today announced that the U.S. Food and Drug Administration (FDA) has extended the original Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) for GSK1838262/XP13512 (gabapentin enacarbil) to February 9, 2010. The original PDUFA date for this NDA review was November 9, 2009. [More]

Posted in: Pharmaceutical News

Tags: , , , , ,

Permalink | Comments (0)

Brain researcher finds how the epilepsy and pain drug works

14. October 2009 05:43
A Duke University Medical Center researcher who spent years looking for the signals that prompt the brain to form new connections between neurons has found one that may explain precisely how a well-known drug for epilepsy and pain actually works. [More]

Posted in: Medical Science News | Pharmaceutical News

Tags: , , , , , , , , ,

Permalink | Comments (0)

Depomed announces results from BREEZE 1 and 2 Phase 3 clinical trials of Serada

12. October 2009 07:57
Depomed, Inc. announced today top-line results from the BREEZE 1 and 2 Phase 3 clinical trials evaluating the safety and efficacy of SeradaTM, an investigational non-hormonal extended release formulation of gabapentin for the treatment of menopausal hot flashes. [More]

Posted in: Drug Trial News

Tags: , , , , , , , , ,

Permalink | Comments (0)

Positive results from Depomed's Phase 3 clinical trial of DM-1796 for postherpetic neuralgia

5. October 2009 07:42
Depomed, Inc. today announced top-line results from a Phase 3 clinical trial demonstrating DM-1796 (also referred to as gabapentin ER) achieved a statistically significant reduction in pain associated with postherpetic neuralgia (PHN) versus placebo using the baseline observation carried forward (BOCF) method required by FDA. [More]

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , , , , ,

Permalink | Comments (0)

GSK reports positive Phase II results from trial evaluating GSK1838262 for post-herpetic neuralgia

5. October 2009 07:08
GlaxoSmithKline and XenoPort, Inc. today announced top-line results from a Phase II clinical trial evaluating GSK1838262/XP13512 (gabapentin enacarbil) in adult patients with neuropathic pain associated with post-herpetic neuralgia (PHN) who have had a history of inadequate response to gabapentin doses of 1800 mg/day or higher. [More]

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , ,

Permalink | Comments (0)

New drug combination releives neuropathic pain and improves sleep

1. October 2009 02:05
People who suffer from debilitating neuropathic pain may get more relief and sleep better by combining two commonly-prescribed drugs. [More]

Posted in: Medical Condition News

Tags: , , , , , , , , , , , , , , ,

Permalink | Comments (0)

Journal publishes Hythiam's PROMETA treatment program results

29. September 2009 06:39
Hythiam, Inc. announced today that the results of a double-blind, placebo-controlled study on the impact of the medical component of the PROMETA® Treatment Program on alcohol dependent subjects was accepted and published in the Journal of Clinical Psychopharmacology, a leading scholarly publication in psychopharmacology that features articles reporting on clinical trials and studies. [More]

Posted in: Pharmaceutical News

Tags: , ,

Permalink | Comments (0)

Results from Phase IIb clinical trial evaluating the safety and efficacy of GSK1838262/XP13512 announced

17. September 2009 07:02
GlaxoSmithKline (NYSE:GSK) and XenoPort, Inc. (Nasdaq:XNPT) today announced top-line results from a Phase IIb clinical trial evaluating the safety and efficacy of GSK1838262/XP13512 (gabapentin enacarbil) for neuropathic pain associated with post-herpetic neuralgia (PHN) in adults. [More]

Posted in: Drug Trial News

Tags: , , , , , , , ,

Permalink | Comments (0)

Gabapentin improves sleep quality in menopausal women

9. September 2009 03:59
Gabapentin, a drug initially used to treat seizures, improves sleep quality in menopausal women with hot flashes, University of Rochester Medical Center researchers report online and in the September issue of the Journal of Women's Health. [More]

Posted in: Women's Health News | Pharmaceutical News

Tags: , , , , , , , , , ,

Permalink | Comments (0)

Compound from coral offers hope fpr neuropathic pain

4. August 2009 19:55
A compound initially isolated from a soft coral (Capnella imbricata) collected at Green Island off Taiwan, could lead scientists to develop a new set of treatments for neuropathic pain - chronic pain that sometimes follows damage to the nervous system. [More]

Posted in: Medical Science News | Medical Research News

Tags: , , , , , , , , , ,

Permalink | Comments (0)

Pregabalin shows potential as treatment for hot flashes

17. May 2009 05:59
A pill used for nerve pain offers women relief from hot flashes, Mayo Clinic researchers report at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO). [More]

Posted in: Drug Trial News

Tags: , , , , , , , , , , , ,

Permalink | Comments (0)

Oxycodone effective against shingles pain

26. March 2009 17:43
The painkiller oxycodone is effective at treating the acute pain of shingles, an illness that often causes severe pain which can become long-lasting and sometimes even permanent. [More]

Posted in: Drug Trial News

Tags: , , , , , , , , , , , , , , ,

Permalink | Comments (0)

GSK and XenoPort resubmit NDA for Solzira in restless legs syndrome

12. January 2009 21:42
GlaxoSmithKline and XenoPort, Inc. announced today that GSK has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of Solzira(TM) (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS). [More]

Posted in: Pharmaceutical News

Tags: , ,

Permalink | Comments (0)
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.